This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Hyperglycosylated follicle stimulating hormone (FSH)

Merck KGaA

Drug Names(s): Hyperglycosylated follicle stimulating hormone (FSH)

Description: This is a third generation FSH (follicle stimulating hormone). FSH is the central hormone of mammalian reproduction, necessary for gonadal development and maturation at puberty and for gamete production during the fertile phase of life. Together with Leutinizing Hormone, this gonadotropin is produced and secreted by the pituitary gland and acts by binding to specific FSH receptors localized exclusively in the gonads.

Deal Structure: In January 2007, the acquisition of Serono S.A. (now Merck Serono S.A.) by Merck KGaA and the integration of the business with the former Merck KGaA Ethicals Division was completed. Merck Serono is now the division of Merck KGaA which specializes in prescription pharmaceuticals. Its North American business operates in the United States and Canada under EMD Serono.

Hyperglycosylated follicle stimulating hormone (FSH) News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug